BioScience, Inc.

BIND Biosciences subleases space

The Boston Business Journal (Free subscription) | yesterday

BIND Biosciences Inc. subleased 26,148 square feet from Alkermes Inc. at 64 Sidney St. in University Park at MIT in Cambridge.

Arcadia gets $3.6M grant to develop crops in India

The Sacramento Business Journal (Free subscription) | yesterday

Arcadia Biosciences Inc. has received a $3.6 million grant to develop rice and wheat in India that use less fertilizer and water.

• Arcadia Biosciences Receives $3.6 Million USAID Grant to Develop Improved Crops in India - Business Wire

Business - Top 5 cos in Deloitte's 2008 Tech Fast 500

Good Read (Free subscription) | 26/11/2008

Hughes Communications Inc., is the fastest growing technology company in North America, followed by Ticket Software LLC, Starent Networks Corp., Abraxis BioScience Inc. and Pure Digital Technologies Inc., according to the 2008 Deloitte Technology Fast 500. The award is a ranking of the fastest growing technology, media, telecommunications and life sciences companies in North...

AK Steel, General Cable gain with markets

The Business Courier of Cincinnati (Free subscription) | 26/11/2008

Other stocks whose fortunes are tied to perceptions of the economy rewarded investors Wednesday. Ashland Inc. (NYSE: ASH), LCA-Vision Inc. (NASDAQ: LCAV) and department store operator Macy’s Inc. (NYSE: M) each posted hefty, market-beating gains Wednesday. Cintas Corp. (NASDAQ: CTAS), Chemed Corp. (NYSE: CHE) and LSI Industries Inc. (NASDAQ: LYTS) also generated big returns....

AstraZeneca plans to end Abraxis deal

Seattle Times (Free subscription) | 25/11/2008

AstraZeneca PLC and U.S.-based Abraxis BioScience Inc. are considering ending their two-year marketing deal for breast cancer treatment Abraxane in the United States.

• AstraZeneca plans to end Abraxis deal - Miami Herald
• AstraZeneca plans to end Abraxis deal - San Fransisco Chronicle

AstraZeneca plans to end Abraxis deal

Miami Herald (Free subscription) | 25/11/2008

AstraZeneca PLC and U.S.-based Abraxis BioScience Inc. are considering ending their two-year marketing deal for breast cancer treatment Abraxane in the United States.

AstraZeneca plans to end Abraxis deal

San Fransisco Chronicle (Free subscription) | 25/11/2008

AstraZeneca PLC and U.S.-based Abraxis BioScience Inc. are considering ending their two-year marketing deal for breast cancer treatment Abraxane in the United States. AstraZeneca said Tuesday that the Abraxis board will consider in early January whether to...